Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
January 20 2016 - 8:05AM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company focused on developing therapeutics to
stimulate the body's immune system to fight cancer, today announced
that members of the company’s scientific team will deliver podium
presentations focused on the role of combination immunotherapies in
the treatment of cancer at two upcoming immunotherapy
conferences. Jeff T. Hutchins, Ph.D., Peregrine’s vice
president, preclinical research, will speak at Immunotherapy World
2016, being held January 25-27, 2016 in Washington, D.C.
Additionally, Bruce Freimark, Ph.D., research director,
preclinical oncology at Peregrine, will present at GTCBio’s 8th
Immunotherapeutics & Immunomonitoring Conference, being held
January 25-26, 2016 in San Diego, CA.
Details of the presentations are as follows:
Immunotherapy World 2016
Title: “Combination Immunotherapies – Opening
the Gate: Increasing Tumor Infiltrating Activated T-Cells to
Optimize and Expand the Benefits of Immune Checkpoint
Therapies.”
Presenter: Dr. Hutchins
Time/Date: Monday, January 25 at 3:40 p.m.
Eastern time.
8th Immunotherapeutics &
Immunomonitoring Conference
Title: “Blockade of Phosphatidylserine Enhances
the Anti-Tumor Activity of Targeted Therapy and Immune Checkpoint
Inhibitors by Reducing Immunosuppressive Cells in the Tumor
Microenvironment.”
Presenter: Dr. Freimark
Time/Date: Tuesday, January 26 at 10:00 a.m.
Pacific time.
In his talk, Dr. Hutchins will discuss
strategies for expanding the therapeutic benefit seen with
immuno-oncology monotherapies to a broader range of patients using
combination treatment approaches. Specifically, he will
highlight the strategy of leveraging treatments capable of
increasing the number and activity of T-cells in the tumor
microenvironment to optimize the therapeutic benefit of immune
checkpoint inhibitors such as anti-PD-1/anti-PDL-1
agents.
Dr. Hutchins will draw on the company’s
experience in working with preclinical equivalents of bavituximab,
Peregrine’s lead investigational phosphatidylserine (PS)-targeting
immunotherapy candidate. PS-targeting antibodies have been shown to
shift the immunosuppressive functions of immune cells in tumors,
resulting in anti-tumor immune responses. Peregrine has
generated results from multiple preclinical and
clinical-translational studies demonstrating enhanced anti-tumor
activity and immune activation when combining equivalent
PS-targeting antibodies with conventional chemotherapy or
checkpoint inhibitors such as anti-PD-1 agents.
Dr. Freimark will highlight data showing that
blocking PS signaling in combination with immune checkpoint
inhibitors promotes a localized, anti-tumor response. He will
share research findings demonstrating that PS-targeting antibodies
enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1
antibodies in models of melanoma and breast cancer and correlate
with an increase in the infiltration of activated T-cells and the
induction of adaptive immunity.
Both presentations will also highlight key
recent research findings showing that PS-signaling pathway
inhibitors demonstrate multiple signs of immune activation in low
or negative PD-L1 tumors. This suggests that PS-targeting
antibodies have the potential to show a clinical benefit in
patients with low PD-L1 levels and who do not generally benefit
from checkpoint treatment alone. The potential for
bavituximab to improve the clinical outcome of checkpoint
inhibitors will be evaluated as part of Peregrine’s ongoing
clinical research collaboration with AstraZeneca. To this
end, a global Phase II study of bavituximab in combination with
AstraZeneca’s durvalumab, an anti-PD-L1 immune checkpoint
inhibitor, in patients with previously treated squamous or
non-squamous NSCLC is expected to begin during the first quarter of
2016.
About Bavituximab: A Targeted
Investigational ImmunotherapyBavituximab is an
investigational chimeric monoclonal antibody that targets
phosphatidylserine (PS). Signals from PS inhibit the ability of
immune cells to recognize and fight tumors. Bavituximab blocks PS
and, in turn, is believed to remove this immunosuppressive signal
and send an alternate immune activating signal. PS targeting
antibodies have been shown to shift the functions of immune cells
in tumors, resulting in robust anti-tumor immune
responses.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company focused on developing therapeutics to stimulate the body's
immune system to fight cancer. Bavituximab, the company's
lead immunotherapy candidate, is in clinical development for the
treatment of both lung cancer and breast cancer. The company
will also evaluate the combination of bavituximab and durvalumab,
AstraZeneca’s investigational anti-PD-L1 immune checkpoint
inhibitor, in a range of cancer types under a clinical
collaboration.
In addition to its drug development programs,
Peregrine also has in-house cGMP manufacturing capabilities through
its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. For more
information, please visit www.peregrineinc.com.
Safe Harbor Statement:
Statements in this press release which are not purely historical,
including statements regarding Peregrine Pharmaceuticals'
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The forward-looking statements involve risks
and uncertainties including, but not limited to, the risk that the
company may experience delays in initiating planned clinical trials
and the risk that future trials may not support earlier research
finding that bavituximab has the ability to enhance the efficacy of
checkpoint inhibitors and convert patients who do not respond to
checkpoint therapy alone into responders. The company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, uncertainties
associated with completing preclinical and clinical trials for our
technologies; the early stage of product development; the
significant costs to develop our products as all of our products
are currently in development, preclinical studies or clinical
trials; obtaining additional financing to support our operations
and the development of our products; obtaining regulatory approval
for our technologies; anticipated timing of regulatory filings and
the potential success in gaining regulatory approval and complying
with governmental regulations applicable to our business. Our
business could be affected by a number of other factors, including
the risk factors listed from time to time in our reports filed with
the Securities and Exchange Commission including, but not limited
to, our annual report on Form 10-K for the fiscal year ended April
30, 2015 as well as any updates to these risk factors filed from
time to time in the company's other filings with the Securities and
Exchange Commission. The company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. Peregrine Pharmaceuticals, Inc. disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024